ALK and non-small cell lung carcinoma: Crizotinib, an oral first generation tyrosine kinase inhibitor of ALK, c-ros oncogene 1 (ROS-1), and c-met proto-oncogene product (c-MET) [7–10], significantly increased therapeutic response and progress-free survival (PFS) in patients with advanced NSCLC with ALK fusion or rearrangement in comparison with standard chemotherapy as first-line treatment [11, 12].